Research sheds light on crimean-congo hemorrhagic fever disease process
Peer-Reviewed Publication
Army scientists determined that the body’s own natural immune response contributes to disease severity in mice infected with Crimean-Congo hemorrhagic fever virus (CCHFV), which causes a widespread tick-borne viral infection in humans. Their work, published May 19, 2022 in PLoS Pathogens, provides a deeper understanding of how the virus causes disease and forms a basis for developing medical countermeasures to prevent and treat infection.
Detecting these T cells may lead to diagnostics to better detect heart disease—and disease severity—through a blood sample. The knowledge also brings researchers closer to developing a vaccine that dampens this dangerous immune cell activity to prevent atherosclerosis.
Two recent discoveries co-led by scientists at Cedars-Sinai may help lead to new ways to treat patients with Allan-Herndon-Dudley syndrome (AHDS), a brain development disorder that causes severe intellectual disability and problems with movement.
James Bibb, Ph.D., and colleagues have described a novel preclinical drug that could have the potential to combat depression, brain injury and diseases that impair cognition. The drug, which notably is brain-permeable, acts to inhibit the kinase enzyme Cdk5.
Press registration is open for the Ecological Society of America’s Annual Meeting, August 14-19, at the Montréal Convention Centre. Program highlights include sessions on zoonoses and the agricultural matrix, nature-based design in urban landscapes, cross-boundary fire ecology, tree species migration and more.
Scientists from St. Jude Children’s Research Hospital uncovered how one type of T cell creates two genetically identical, but functionally different, daughter cells.
About The Study: This study of 401 patient safety reports examined whether there is bias in how events are reported based on the race and ethnicity, gender or faculty rank of the physician who is the subject of the event report.